Car-t cell therapy for multiple myeloma that has relapsed
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial studies a type of cancer treatment called CAR-T cell therapy for people with multiple myeloma that has relapsed (come back) or is refractory (did not respond to treatment). The treatment uses your own immune cells to attack the cancer. This study is real-world, meaning it happens in everyday clinical practice, not in a strict research setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- You have multiple myeloma that has come back or did not respond to previous treatment.
- Your doctor has decided to give you this treatment as part of your regular care.
- You are not allergic to the ingredients in this treatment (including DMSO, compound electrolyte injection, or human albumin).
- You are able to attend all necessary follow-up visits.
- Your doctor expects you to live for at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR T-cell therapy for people with multiple myeloma that has returned or not responded to standard treatments. The therapy uses your own immune cells, modified to attack the cancer, which may help you achieve a remission.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
This trial tests a new treatment using your own immune cells (called CAR-T cells) to fight multiple myeloma that has returned or not responded to earlier treatments. The treatment is designed to target and kill myeloma cells more effectively.
This trial is testing a new cell therapy (called Eque-cel) for people with multiple myeloma that has come back or stopped responding to standard treatments. The therapy uses your own immune cells to attack the myeloma cells. You may qualify if you've tried at least three prior treatment combinations.
This study tests a new CAR-T cell therapy called Eque-cel for people with multiple myeloma that no longer responds to lenalidomide. It aims to see if this treatment can help control the disease after 1-2 prior therapies.
This trial tests a special type of immune therapy called CAR T cells, which are made from your own blood cells and then given back to you to fight the cancer. It is for people with multiple myeloma who have not gotten better with other treatments or whose cancer has come back.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.